AVDL News and Press, Avadel Pharmaceuticals plc From 12/15/20

Avadel's FT218 is claimed to be a better version of Xyrem. Xyrem, or rather sodium oxybate, is a multibillion-dollar market. Key competition now is, however, Xywav. For further details see: Avadel's Xyrem Competitor: A Quick Overview

DUBLIN, Ireland, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, ...

DUBLIN, Ireland, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced ...

DUBLIN, Ireland, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced ...

Image source: The Motley Fool. Avadel Pharmaceuticals plc (NASDAQ: AVDL) Q3 2020 Earnings Call Nov 9, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: Avadel Pharmaceuticals plc (AVDL) Q3 2020 Earnings Call Transcrip...

Avadel Pharmaceuticals plc (AVDL) Q3 2020 Earnings Conference Call November 09, 2020, 08:30 AM ET Company Participants Thomas McHugh - CFO Greg Divis - CEO Conference Call Participants David Amsellem - Piper Sandler Paul Matteis - Stifel Francois Brisebois - Oppenheimer Matt Kaplan - Ladenbur...

Avadel Pharmaceuticals plc (AVDL) Q3 2020 Earnings Conference Call November 9, 2020 8:20 A.M. ET Company Participants Thomas McHugh - Chief Financial Officer Greg Divis - Chief Executive Officer Conference Call Participants David Amsellem - Piper Jaffray Paul Matthews - Stifel Oren Livnat - H...

Avadel Pharmaceuticals (AVDL): Q3 GAAP EPS of -$0.20 beats by $0.04.Cash, cash equivalents and marketable securities of $231.6MPress Release For further details see: Avadel Pharmaceuticals EPS beats by $0.04

NDA for once-nightly FT218 is on track for FDA submission by end of December 2020 New market assessment data identifies a significant potential marke t expansion opportunity for once-nightly FT218 be...

DUBLIN, Ireland, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, annou...